Hofbauer, Joshua and Hauck, Andreas and Matos, Carina and Babl, Nathalie and Decking, Sonja-Maria and Rechenmacher, Michael and Schulz, Christian and Regotta, Sabine and Mickler, Marion and Haferkamp, Sebastian and Siska, Peter J. and Herr, Wolfgang and Renner, Kathrin and Kreutz, Marina and Schnell, Annette (2022) Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy. BIOMOLECULES, 12 (5): 716. ISSN , 2218-273X
Full text not available from this repository. (Request a copy)Abstract
Although the discovery of immune checkpoints was hailed as a major breakthrough in cancer therapy, generating a sufficient response to immunotherapy is still limited. Thus, the objective of this exploratory, hypothesis-generating study was to identify potentially novel peripheral biomarkers and discuss the possible predictive relevance of combining scarcely investigated metabolic and hormonal markers with immune subsets. Sixteen markers that differed significantly between responders and non-responders were identified. In a further step, the correlation with progression-free survival (PFS) and false discovery correction (Benjamini and Hochberg) revealed potential predictive roles for the immune subset absolute lymphocyte count (rs = 0.51; p = 0.0224 *), absolute basophil count (rs = 0.43; p = 0.04 *), PD-1+ monocytes (rs = -0.49; p = 0.04 *), hemoglobin (rs = 0.44; p = 0.04 *), metabolic markers LDL (rs = 0.53; p = 0.0224 *), free androgen index (rs = 0.57; p = 0.0224 *) and CRP (rs = -0.46; p = 0.0352 *). The absolute lymphocyte count, LDL and free androgen index were the most significant individual markers, and combining the immune subsets with the metabolic markers into a biomarker ratio enhanced correlation with PFS (rs = -0.74; p <= 0.0001 ****). In summary, in addition to well-established markers, we identified PD-1+ monocytes and the free androgen index as potentially novel peripheral markers in the context of immunotherapy. Furthermore, the combination of immune subsets with metabolic and hormonal markers may have the potential to enhance the power of future predictive scores and should, therefore, be investigated further in larger trials.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CELL LUNG-CANCER; CHOLESTEROL; CD147; NIVOLUMAB; COMBINATION; BIOMARKERS; CACHEXIA; PD-1; immunotherapy; PD-1+ monocytes; metabolism; hormones; immune cells; cholesterol; testosterone; free androgen index; hemoglobin |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Innere Medizin II Medicine > Zentren des Universitätsklinikums Regensburg > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Nov 2023 14:14 |
| Last Modified: | 14 Nov 2023 14:14 |
| URI: | https://pred.uni-regensburg.de/id/eprint/56754 |
Actions (login required)
 |
View Item |
